title: Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.
abstract: Antiresorptive therapies are used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease related to breast cancer, prostate cancer, and other solid tumors. This review highlights the central role of nurses in supporting and educating advanced cancer patients regarding the consequences of bone metastases and SREs, including therapy management options. Contemporary clinical journals reporting evidence-based studies were reviewed. SREs associated with bone metastases can significantly impact the quality of life of advanced cancer patients. Denosumab therapy, an advancement in antiresorptive treatments, significantly prevents and delays the time to develop SREs. In the multifaceted approach required for successful and consistent management of SREs associated with bone metastases, antiresorptive therapies can play a central role in maintaining the functional independence of patients through the prevention of debilitating SREs, thereby preserving quality of life.
authors: Department of Oncology, Penn State Hershey Medical Center, 500 University Drive, H046, C6615, Hershey, PA, 17033, USA. cbaird@hmc.psu.edu.
authors: Cynthia
authors: C
authors: Campbell-Baird
authors: Carolina Urologic Research Center, 823 82nd Parkway, Suite B, Myrtle Beach, SC, 29572, USA.
authors: Stacey
authors: S
authors: Harrelson
authors: Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, AZ, 85724, USA.
authors: Georgette
authors: G
authors: Frey
authors: Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
authors: Arun
authors: A
authors: Balakumaran
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D000069448:Denosumab / Q000008:administration & dosage / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009729:Nursing; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D000069448:Denosumab
keywords: Antiresorptive; Bisphosphonates; Bone metastases; Denosumab; Skeletal-related events